{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:24Z","timestamp":1793756364652,"version":"4.6.1"},"reference-count":395,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmr.2025.100106","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:32:54Z","timestamp":1763692374000},"page":"100106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metformin\u2014mechanisms of its glycemia-reducing effect"],"prefix":"10.1016","volume":"78","author":[{"given":"J\u00fcrgen","family":"Drewe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-9032","authenticated-orcid":false,"given":"Marc","family":"Foretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-4145","authenticated-orcid":false,"given":"Stephan","family":"Kr\u00e4henb\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib1","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/M20-2470","article-title":"Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association\u2019s standards of medical care in diabetes clinical guideline","volume":"173","author":"Doyle-Delgado","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society Clinical Practice Guideline. Clinical Practice Guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M16-1860","article-title":"Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9131","key":"10.1016\/j.pharmr.2025.100106_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and molecular mechanisms of metformin action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the intestine","volume":"51","author":"Bailey","year":"2008","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100106_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108824","article-title":"Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"178","author":"Abrilla","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharmr.2025.100106_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101517","article-title":"Mechanisms of action of metformin in type 2 diabetes: effects on mitochondria and leukocyte-endothelium interactions","volume":"34","author":"Apostolova","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.pharmr.2025.100106_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.682853","article-title":"Metformin, macrophage dysfunction and atherosclerosis","volume":"12","author":"Feng","year":"2021","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100106_bib14","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.3390\/ijms22179453","article-title":"New insight into the effects of metformin on diabetic retinopathy, aging and cancer: nonapoptotic cell death, immunosuppression, and effects beyond the AMPK pathway","volume":"22","author":"Hsu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib15","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/ijms22052596","article-title":"Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history","volume":"22","author":"Kaneto","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s43440-021-00334-z","article-title":"An update on mode of action of metformin in modulation of meta-inflammation and inflammaging","volume":"74","author":"Khodadadi","year":"2022","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/biof.1548","article-title":"Mitochondrial targets of metformin-Are they physiologically relevant?","volume":"45","author":"Pecinov\u00e1","year":"2019","journal-title":"BioFactors"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s42000-019-00093-w","article-title":"Metformin and gut microbiota: their interactions and their impact on diabetes","volume":"18","author":"Vallianou","year":"2019","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.pharmr.2025.100106_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fendo.2019.00294","article-title":"Role of mitochondria in the mechanism(s) of action of metformin","volume":"10","author":"Vial","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib20","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib21","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin-dependent diabetes mellitus","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ndt\/gfaa302","article-title":"Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism","volume":"37","author":"Legouis","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1172\/JCI106016","article-title":"Liver and kidney metabolism during prolonged starvation","volume":"48","author":"Owen","year":"1969","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biocel.2011.10.001","article-title":"Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis","volume":"44","author":"Jitrapakdee","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of hepatic glucose metabolism in health and disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"7798","key":"10.1016\/j.pharmr.2025.100106_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/BCJ20220582","article-title":"AMPK inhibits liver gluconeogenesis: fact or fiction?","volume":"480","author":"Johanns","year":"2023","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib29","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1152\/ajpendo.00126.2006","article-title":"Perturbation of glucose flux in the liver by decreasing F26P2 levels causes hepatic insulin resistance and hyperglycemia","volume":"291","author":"Wu","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib31","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1073\/pnas.73.8.2762","article-title":"Hormonal control of pyruvate kinase activity and of gluconeogenesis in isolated hepatocytes","volume":"73","author":"Feli\u00fa","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7396","key":"10.1016\/j.pharmr.2025.100106_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature10988","article-title":"Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes","volume":"485","author":"Wang","year":"2012","journal-title":"Nature"},{"issue":"39","key":"10.1016\/j.pharmr.2025.100106_bib33","doi-asserted-by":"crossref","first-page":"30169","DOI":"10.1074\/jbc.M004898200","article-title":"Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix\/forkhead proteins","volume":"275","author":"Hall","year":"2000","journal-title":"J Biol Chem"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100106_bib34","doi-asserted-by":"crossref","first-page":"36324","DOI":"10.1074\/jbc.M003616200","article-title":"Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity","volume":"275","author":"Schmoll","year":"2000","journal-title":"J Biol Chem"},{"issue":"6939","key":"10.1016\/j.pharmr.2025.100106_bib35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nature01667","article-title":"Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction","volume":"423","author":"Puigserver","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib36","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1210\/en.2017-00525","article-title":"FOX01 is the headline Akt regulating hepatic glucose metabolism","volume":"158","author":"Smith","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100106_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101304","article-title":"Insulin action at a molecular level \u2212100 years of progress","volume":"52","author":"White","year":"2021","journal-title":"Mol Metab"},{"issue":"7147","key":"10.1016\/j.pharmr.2025.100106_bib38","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/nature05861","article-title":"Akt\/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator","volume":"447","author":"Li","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00011.2008","article-title":"AMPK in health and disease","volume":"89","author":"Steinberg","year":"2009","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmet.2015.05.005","article-title":"Beyond energy homeostasis: the expanding role of AMP-activated protein kinase in regulating metabolism","volume":"21","author":"Carling","year":"2015","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7665","key":"10.1016\/j.pharmr.2025.100106_bib43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature23275","article-title":"Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK","volume":"548","author":"Zhang","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib44","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cmet.2014.06.014","article-title":"The lysosomal V-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism","volume":"20","author":"Zhang","year":"2014","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib45","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41422-019-0163-6","article-title":"Hierarchical activation of compartmentalized pools of AMPK depends on severity of nutrient or energy stress","volume":"29","author":"Zong","year":"2019","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13435","article-title":"Insulin regulation of gluconeogenesis","volume":"1411","author":"Hatting","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"42","key":"10.1016\/j.pharmr.2025.100106_bib47","doi-asserted-by":"crossref","first-page":"32182","DOI":"10.1074\/jbc.M110.134890","article-title":"AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner","volume":"285","author":"Lee","year":"2010","journal-title":"J Biol Chem"},{"issue":"6852","key":"10.1016\/j.pharmr.2025.100106_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35093131","article-title":"CREB regulates hepatic gluconeogenesis through the coactivator PGC-1","volume":"413","author":"Herzig","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100106_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10856","article-title":"AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B","volume":"7","author":"Johanns","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib50","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1042\/BCJ20220170","article-title":"Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other pharmacological AMPK activators","volume":"479","author":"Johanns","year":"2022","journal-title":"Biochem J"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib52","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100106_bib53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK re-activation suppresses hepatic steatosis but its downregulation does not promote fatty liver development","volume":"28","author":"Boudaba","year":"2018","journal-title":"EBiomedicine"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.cmet.2017.04.010","article-title":"Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human Primates and mice","volume":"25","author":"Cokorinos","year":"2017","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib55","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1074\/jbc.M113.528232","article-title":"5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo","volume":"289","author":"Hasenour","year":"2014","journal-title":"J Biol Chem"},{"issue":"7506","key":"10.1016\/j.pharmr.2025.100106_bib56","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0410-392","article-title":"Neuronal regulation of homeostasis by nutrient sensing","volume":"16","author":"Lam","year":"2010","journal-title":"Nat Med"},{"issue":"7121","key":"10.1016\/j.pharmr.2025.100106_bib58","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nature05484","article-title":"Gut hormones and the regulation of energy homeostasis","volume":"444","author":"Murphy","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cmet.2017.09.019","article-title":"Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway","volume":"27","author":"Bauer","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nm1201","article-title":"Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis","volume":"11","author":"Lam","year":"2005","journal-title":"Nat Med"},{"issue":"7190","key":"10.1016\/j.pharmr.2025.100106_bib61","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/nature06852","article-title":"Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production","volume":"452","author":"Wang","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s12276-021-00677-w","article-title":"Role of the gut-brain axis in energy and glucose metabolism","volume":"54","author":"Wachsmuth","year":"2022","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib63","first-page":"300","article-title":"Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1","volume":"20","author":"Gastaldelli","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib64","doi-asserted-by":"crossref","first-page":"E701","DOI":"10.1152\/ajpendo.00024.2003","article-title":"Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect","volume":"285","author":"Prigeon","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","article-title":"Direct effect of GLP-1 infusion on endogenous glucose production in humans","volume":"56","author":"Seghieri","year":"2013","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib66","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib67","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib68","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.28","article-title":"Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-\u03b4-dependent neurocircuitry","volume":"8","author":"Yang","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmr.2025.100106_bib70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.semcdb.2023.07.010","article-title":"Vagal pathways for systemic regulation of glucose metabolism","volume":"156","author":"Borgmann","year":"2024","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0026-0495(94)90164-3","article-title":"Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man","volume":"43","author":"Hvidberg","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2025.100106_bib72","article-title":"Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib74","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib75","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/BF02658511","article-title":"GLP-1 does not acutely affect insulin sensitivity in healthy man","volume":"39","author":"Orskov","year":"1996","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bph.15638","article-title":"Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment","volume":"179","author":"Trapp","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib77","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1042\/bj0311268","article-title":"The metabolism of lactic and pyruvic acids in normal and tumour tissues: synthesis of carbohydrate","volume":"31","author":"Benoy","year":"1937","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib78","first-page":"E78","article-title":"Insulin regulation of renal glucose metabolism in humans","volume":"276","author":"Cersosimo","year":"1999","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4239\/wjd.v12.i5.556","article-title":"Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes","volume":"12","author":"Sharma","year":"2021","journal-title":"World J Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","article-title":"Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus","volume":"102","author":"Meyer","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249594","article-title":"Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues","volume":"16","author":"Zake","year":"2021","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib82","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040535","article-title":"Glycolysis","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib83","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040568","article-title":"Carbohydrate metabolism","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib84","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/dom.12697","article-title":"Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin","volume":"18","author":"Bahne","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib85","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/BF00356171","article-title":"Human glucokinase regulatory protein (GCKR): cDNA and genomic cloning, complete primary structure, and chromosomal localization","volume":"6","author":"Warner","year":"1995","journal-title":"Mamm Genome"},{"key":"10.1016\/j.pharmr.2025.100106_bib86","article-title":"Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmr.2025.100106_bib87","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.nu.11.070191.002341","article-title":"Hepatic gluconeogenesis\/glycolysis: regulation and structure\/function relationships of substrate cycle enzymes","volume":"11","author":"Pilkis","year":"1991","journal-title":"Annu Rev Nutr"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib88","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1073\/pnas.75.10.5173","article-title":"Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange","volume":"75","author":"DeFronzo","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib89","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2337\/diab.30.12.1000","article-title":"The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization","volume":"30","author":"DeFronzo","year":"1981","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib90","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1172\/JCI113011","article-title":"Kinetics of glucose disposal in whole body and across the forearm in man","volume":"79","author":"Yki-J\u00e4rvinen","year":"1987","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","article-title":"Glucose transporters: physiological and pathological roles","volume":"8","author":"Navale","year":"2016","journal-title":"Biophys Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib92","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM199907223410406","article-title":"Glucose transporters and insulin action\u2014implications for insulin resistance and diabetes mellitus","volume":"341","author":"Shepherd","year":"1999","journal-title":"N Engl J Med"},{"issue":"1 suppl 1","key":"10.1016\/j.pharmr.2025.100106_bib93","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib95","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib97","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib98","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","article-title":"Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis","volume":"12","author":"Usman","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100106_bib99","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1074\/jbc.270.15.8971","article-title":"Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization","volume":"270","author":"Heimberg","year":"1995","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00424-020-02466-2","article-title":"Cellular and systemic mechanisms for glucose sensing and homeostasis","volume":"472","author":"Sohn","year":"2020","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib101","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM199907223410404","article-title":"Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes","volume":"341","author":"Cline","year":"1999","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib102","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/78693","article-title":"Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance","volume":"6","author":"Zisman","year":"2000","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib103","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1172\/JCI1557","article-title":"Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance","volume":"101","author":"Garvey","year":"1998","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib104","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/ijms23031264","article-title":"Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport","volume":"23","author":"Herman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100106_bib105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.freeradbiomed.2024.09.004","article-title":"Exercise performance and health: role of GLUT4","volume":"224","author":"McGee","year":"2024","journal-title":"Free Radic Biol Med"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100106_bib106","doi-asserted-by":"crossref","first-page":"14396","DOI":"10.1016\/S0021-9258(17)36636-X","article-title":"Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle","volume":"269","author":"Ren","year":"1994","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib107","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/diabetes.48.8.1667","article-title":"5\u2032 AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle","volume":"48","author":"Kurth-Kraczek","year":"1999","journal-title":"Diabetes"},{"issue":"6350","key":"10.1016\/j.pharmr.2025.100106_bib108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1126\/science.aah5582","article-title":"Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy","volume":"357","author":"Myers","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pdi.606","article-title":"Metformin: its botanical background","volume":"21","author":"Bailey","year":"2004","journal-title":"Pract Diab Int"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13568-022-01409-7","article-title":"Improving galegine production in transformed hairy roots of Galega officinalis L. via elicitation","volume":"12","author":"Khezri","year":"2022","journal-title":"AMB Express"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib111","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100106_bib112","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1039\/CT9222101790","article-title":"The preparation of methylguanidine, and of \u03b2,\u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides, respectively","volume":"121","author":"Werner","year":"1922","journal-title":"J Chem Soc Trans"},{"issue":"5-6","key":"10.1016\/j.pharmr.2025.100106_bib113","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF02000097","article-title":"Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel","volume":"142","author":"Hesse","year":"1929","journal-title":"Archiv f experiment Pathol u Pharmakol"},{"issue":"45","key":"10.1016\/j.pharmr.2025.100106_bib114","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/BF01736560","article-title":"\u00dcber synthetisch dargestellte K\u00f6rper mit insulinartiger Wirkung auf den normalen und diabetischen Organismus","volume":"5","author":"Frank","year":"1926","journal-title":"Klin Wochenschr"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib115","first-page":"287","article-title":"Flumamine, a new synthetic analgesic and anti-flu drug","volume":"26","author":"Garcia","year":"1950","journal-title":"J Philipp Med Assoc"},{"key":"10.1016\/j.pharmr.2025.100106_bib116","first-page":"625","article-title":"Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)","volume":"14","author":"Sterne","year":"1959","journal-title":"Therapie"},{"key":"10.1016\/j.pharmr.2025.100106_bib117","first-page":"1561","article-title":"[3 years of treatment of diabetes by dimethyl-guanylguanidine hydrochloride, LA-6023, Glucophage]","volume":"67","author":"Sterne","year":"1960","journal-title":"Gaz Med Fr"},{"key":"10.1016\/j.pharmr.2025.100106_bib118","first-page":"599","article-title":"Report on 5-years\u2019 experience with dimethylbiguanide (metformin, Glucophage) in diabetic therapy","volume":"113","author":"Sterne","year":"1963","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.pharmr.2025.100106_bib119","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1742-1241.1962.tb06445.x","article-title":"The treatment of diabetes mellitus with metformin","volume":"16","author":"Duncan","year":"1962","journal-title":"Br J Clin Pract"},{"issue":"5279","key":"10.1016\/j.pharmr.2025.100106_bib120","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/bmj.1.5279.680","article-title":"Metformin in treatment of diabetes mellitus","volume":"1","author":"Gottlieb","year":"1962","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib121","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00002018-199411040-00002","article-title":"Comparative tolerability profiles of oral antidiabetic agents","volume":"11","author":"Krentz","year":"1994","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib122","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01263444","article-title":"Lactic acidosis in biguanide-treated diabetics: a review of 330 cases","volume":"14","author":"Luft","year":"1978","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib123","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3803\/EnM.2015.30.1.78","article-title":"Metformin-associated lactic acidosis: predisposing factors and outcome","volume":"30","author":"Kim","year":"2015","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2710.2010.01192.x","article-title":"Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements","volume":"36","author":"van Berlo-van de Laar","year":"2011","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib126","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF00285334","article-title":"Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus","volume":"32","author":"Groop","year":"1989","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib127","first-page":"257","article-title":"Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes","volume":"120","author":"Hother-Nielsen","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib128","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diab.36.5.632","article-title":"Mechanism of metformin action in non-insulin-dependent diabetes","volume":"36","author":"Jackson","year":"1987","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2337\/diacare.10.1.62","article-title":"Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes","volume":"10","author":"Nosadini","year":"1987","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib130","first-page":"346","article-title":"Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus","volume":"12","author":"Prager","year":"1986","journal-title":"Diabetes Metab"},{"issue":"6972","key":"10.1016\/j.pharmr.2025.100106_bib131","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.310.6972.83","article-title":"13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years","volume":"310","year":"1995","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib132","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jdiacomp.2005.08.010","article-title":"Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73","volume":"20","author":"Wright","year":"2006","journal-title":"J Diabetes Complications"},{"issue":"10448","key":"10.1016\/j.pharmr.2025.100106_bib133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100106_bib134","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100106_bib135","series-title":"World Health Organization Model List of Essential Medicines","year":"2025"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib136","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib137","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00562061","article-title":"Pharmacokinetics of metformin after intravenous and oral administration to man","volume":"16","author":"Pentik\u00e4inen","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.1981.tb01206.x","article-title":"Metformin kinetics in healthy subjects and in patients with diabetes mellitus","volume":"12","author":"Tucker","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib139","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2967\/jnumed.116.177774","article-title":"In vivo imaging of human 11C-Metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses","volume":"57","author":"Gormsen","year":"2016","journal-title":"J Nucl Med"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100106_bib140","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.3748\/wjg.v12.i25.4064","article-title":"Intestinal permeability of metformin using single-pass intestinal perfusion in rats","volume":"12","author":"Song","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib141","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib142","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","article-title":"Clinical pharmacokinetics of metformin","volume":"30","author":"Scheen","year":"1996","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib143","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1124\/dmd.107.020180","article-title":"Mechanisms underlying saturable intestinal absorption of metformin","volume":"36","author":"Proctor","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib144","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/dmd.107.015495","article-title":"Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine","volume":"35","author":"Zhou","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib145","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.xphs.2015.11.040","article-title":"Why does the intestine lack basolateral efflux transporters for cationic compounds? A provocative hypothesis","volume":"105","author":"Proctor","year":"2016","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib146","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1021\/acs.molpharmaceut.5b00501","article-title":"Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3)","volume":"12","author":"Liang","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib147","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00498259409043220","article-title":"Accumulation of metformin by tissues of the normal and diabetic mouse","volume":"24","author":"Wilcock","year":"1994","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib148","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/mol.112.084517","article-title":"Organic cation transporter 1 (OCT1\/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes","volume":"84","author":"Han","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib149","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bcp.2005.09.011","article-title":"Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)","volume":"70","author":"M\u00fcller","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib150","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/db16-0032","article-title":"[11C]-labeled metformin distribution in the liver and small intestine using dynamic positron emission tomography in mice demonstrates tissue-specific transporter dependency","volume":"65","author":"Jensen","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib151","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/jpet.102.034140","article-title":"Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin","volume":"302","author":"Wang","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100106_bib152","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1128\/MCB.21.16.5471-5477.2001","article-title":"Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene","volume":"21","author":"Jonker","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib153","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1248\/bpb.25.1345","article-title":"Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2","volume":"25","author":"Watanabe","year":"2002","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib154","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.2042-7158.1991.tb03507.x","article-title":"Subcellular distribution of metformin in rat liver","volume":"43","author":"Wilcock","year":"1991","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib157","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11095-008-9770-5","article-title":"Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis","volume":"26","author":"Jin","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharmr.2025.100106_bib158","article-title":"Regulation mechanisms of expression and function of organic cation Transporter 1","volume":"11","author":"Ciarimboli","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib159","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.23103","article-title":"Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver","volume":"50","author":"Nies","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100106_bib160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib161","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/j.2040-4603.2013.tb00495.x","article-title":"Physiology of cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib162","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib163","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FPC.0b013e32833fe789","article-title":"Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin","volume":"20","author":"Chen","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib164","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"50","key":"10.1016\/j.pharmr.2025.100106_bib165","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib166","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1262-3636(07)70037-X","article-title":"Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects","volume":"29","author":"Robert","year":"2003","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib167","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11095-004-1193-3","article-title":"Metformin transport by renal basolateral organic cation transporter hOCT2","volume":"22","author":"Kimura","year":"2005","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib168","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.109.056242","article-title":"Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin","volume":"75","author":"Tsuda","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib169","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2009.92","article-title":"The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin","volume":"86","author":"Tzvetkov","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2133\/dmpk.20.379","article-title":"Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1","volume":"20","author":"Kimura","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib171","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2133\/dmpk.20.452","article-title":"Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies","volume":"20","author":"Nishimura","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib172","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/clpt.2011.36","article-title":"Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects","volume":"89","author":"Kusuhara","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib173","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.molpharmaceut.8b00416","article-title":"Importance of OCT2 and MATE1 for the cimetidine-metformin interaction: insights from investigations of polarized transport in single- and double-transfected MDCK cells with a focus on perpetrator disposition","volume":"15","author":"M\u00fcller","year":"2018","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib174","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2967\/jnumed.115.169292","article-title":"A PET tracer for renal organic cation transporters, 11C-Metformin: radiosynthesis and preclinical proof-of-concept studies","volume":"57","author":"Jakobsen","year":"2016","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.123.001470","article-title":"Effect of cimetidine on metformin pharmacokinetics and endogenous metabolite levels in rats","volume":"52","author":"Ailabouni","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100106_bib177","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0020-711X(80)90035-X","article-title":"Quantitative morphology of the rat kidney","volume":"12","author":"Pfaller","year":"1980","journal-title":"Int J Biochem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2022.130171","article-title":"Metformin-ROS-Nrf2 connection in the host defense mechanism against oxidative stress, apoptosis, cancers, and ageing","volume":"1866","author":"Udono","year":"2022","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.pharmr.2025.100106_bib179","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000481951","article-title":"Renoprotective effects of metformin","volume":"138","author":"De Broe","year":"2018","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166912","article-title":"Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats","volume":"1870","author":"Jaikumkao","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib182","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/15376516.2021.1919810","article-title":"Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model","volume":"31","author":"Koroglu-Ayd\u0131n","year":"2021","journal-title":"Toxicol Mech Methods"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib183","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00125-017-4445-6","article-title":"Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats","volume":"61","author":"Qi","year":"2018","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib184","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0006-2952(02)00861-4","article-title":"Inhibition of gluconeogenesis by vanadium and metformin in kidney-cortex tubules isolated from control and diabetic rabbits","volume":"63","author":"Kiersztan","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001076","article-title":"Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register","volume":"2","author":"Ekstr\u00f6m","year":"2012","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib186","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5694\/j.1326-5377.2008.tb01713.x","article-title":"Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study","volume":"188","author":"Kamber","year":"2008","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib187","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of metformin use with risk of lactic acidosis across the range of kidney function: A community-based cohort study","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib188","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2024.08.012","article-title":"Stopping versus continuing metformin in patients with advanced CKD: A nationwide Scottish target trial emulation study","volume":"85","author":"Lambourg","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharmr.2025.100106_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102568","article-title":"Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study","volume":"71","author":"Yang","year":"2024","journal-title":"EClinicalmedicine"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100106_bib190","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib191","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0006-2952(02)00858-4","article-title":"Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function","volume":"63","author":"Detaille","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib192","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1042\/BJ20040885","article-title":"Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study","volume":"382","author":"Guigas","year":"2004","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib193","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib194","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00125-011-2311-5","article-title":"Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status","volume":"54","author":"Stephenne","year":"2011","journal-title":"Diabetologia"},{"issue":"6630","key":"10.1016\/j.pharmr.2025.100106_bib195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1126\/science.ade3332","article-title":"Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides","volume":"379","author":"Bridges","year":"2023","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib196","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/hep.1840150631","article-title":"Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte","volume":"15","author":"Kr\u00e4henb\u00fchl","year":"1992","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib197","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1083\/jcb.37.1.27","article-title":"A quantitative stereological description of the ultrastructure of normal rat liver parenchymal cells","volume":"37","author":"Loud","year":"1968","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmr.2025.100106_bib198","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fendo.2018.00753","article-title":"Metformin-induced mitochondrial Complex I inhibition: facts, uncertainties, and consequences","volume":"9","author":"Fontaine","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib199","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2008-1025758","article-title":"Exercise-induced ultrastructural changes in skeletal muscle","volume":"7","author":"Hoppeler","year":"1986","journal-title":"Int J Sports Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib201","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/0016-5085(87)90269-1","article-title":"Quantitative alterations in the structural development of jejunal absorptive epithelial cells and their subcellular organelles in protein-energy-malnourished rats: a stereologic analysis","volume":"93","author":"da Costa Ribeiro","year":"1987","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib202","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00125-016-3992-6","article-title":"Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials","volume":"59","author":"DeFronzo","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib203","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib204","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203946","article-title":"Improved glycemic control with minimal systemic metformin exposure: effects of metformin Delayed-Release (metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes","volume":"13","author":"Henry","year":"2018","journal-title":"PLOS One"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib205","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1185\/030079904125003278","article-title":"Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study","volume":"20","author":"Blonde","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib206","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2174\/0118715303294909240221102552","article-title":"Improving type 2 diabetes care with extended-release metformin: real-life insights from a physician educational program","volume":"24","author":"Molteni","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib207","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13300-021-01058-2","article-title":"Efficacy and side effect profile of different formulations of metformin: A systematic review and meta-analysis","volume":"12","author":"Tarry-Adkins","year":"2021","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib208","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib209","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jdi.12755","article-title":"Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus","volume":"9","author":"Kanto","year":"2017","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib210","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70055","article-title":"Non-linear dose-response relationship for metformin in Japanese patients with type 2 diabetes: analysis of irregular longitudinal data by interpretable machine learning models","volume":"13","author":"Akimoto","year":"2025","journal-title":"Pharmacol Res Perspect"},{"issue":"suppl 3","key":"10.1016\/j.pharmr.2025.100106_bib211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17906","article-title":"Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies","volume":"9","author":"Sun","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib213","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/diab.41.3.354","article-title":"Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM","volume":"41","author":"Wid\u00e9n","year":"1992","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib214","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1007\/s00125-015-3733-2","article-title":"Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial","volume":"58","author":"Christensen","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib215","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00125-019-05042-1","article-title":"Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals","volume":"63","author":"McCreight","year":"2020","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib216","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cpt.2382","article-title":"Metformin stimulates intestinal glycolysis and lactate release: A single-dose study of metformin in patients with intrahepatic portosystemic stent","volume":"110","author":"Rittig","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib217","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/db07-0827","article-title":"Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes","volume":"57","author":"Basu","year":"2008","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib218","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib219","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2337\/diacare.21.9.1489","article-title":"Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin","volume":"21","author":"Damsbo","year":"1998","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib220","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-73-6-1294","article-title":"Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects","volume":"73","author":"DeFronzo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib221","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/clinem\/dgad669","article-title":"Glycemia and gluconeogenesis with metformin and liraglutide: A randomized trial in youth-onset type 2 diabetes","volume":"109","author":"Dietsche","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib222","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-019-4872-7","article-title":"Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes","volume":"62","author":"Gormsen","year":"2019","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib223","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.2337\/diabetes.51.12.3479","article-title":"Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes","volume":"51","author":"H\u00e4llsten","year":"2002","journal-title":"Diabetes"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100106_bib224","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM199803263381303","article-title":"Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib225","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/0026-0495(93)90284-U","article-title":"The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients","volume":"42","author":"Johnson","year":"1993","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib226","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2337\/diabetes.54.5.1459","article-title":"Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study","volume":"54","author":"Karlsson","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib227","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1053\/meta.2002.50108","article-title":"Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal","volume":"52","author":"Mathieu-Costello","year":"2003","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib228","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1445-5994.1991.tb01375.x","article-title":"Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus","volume":"21","author":"McIntyre","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib229","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","article-title":"Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes","volume":"51","author":"Musi","year":"2002","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib230","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diab.43.7.920","article-title":"Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production","volume":"43","author":"Perriello","year":"1994","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib231","first-page":"1020","article-title":"Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control","volume":"74","author":"Reaven","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"1 Pt 2","key":"10.1016\/j.pharmr.2025.100106_bib232","first-page":"180","article-title":"Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin","volume":"17","author":"Riccio","year":"1991","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib233","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.13.1.1","article-title":"Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients","volume":"13","author":"Wu","year":"1990","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib234","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.701","article-title":"Genetic polymorphisms in organic cation Transporter 1 attenuates hepatic metformin exposure in humans","volume":"102","author":"Sundelin","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/bdd.755","article-title":"Mechanisms for membrane transport of metformin in human intestinal epithelial Caco-2 cells","volume":"32","author":"Horie","year":"2011","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib236","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.molmet.2017.05.002","article-title":"Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state","volume":"6","author":"Schommers","year":"2017","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib237","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1185\/03007998409109558","article-title":"Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects","volume":"9","author":"Bonora","year":"1984","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib238","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1464-5491.1992.tb01716.x","article-title":"The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes","volume":"9","author":"Sum","year":"1992","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib239","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/dc11-0925","article-title":"Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes","volume":"35","author":"Malin","year":"2012","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100106_bib240","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib241","first-page":"E1107","article-title":"AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle","volume":"273","author":"Merrill","year":"1997","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib242","first-page":"E1","article-title":"AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes","volume":"277","author":"Winder","year":"1999","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib243","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00125-012-2482-8","article-title":"Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes","volume":"55","author":"Vind","year":"2012","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib244","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15948","article-title":"Effects of metformin on glucose metabolism and mitochondrial function in patients with obstructive sleep apnea: a pilot randomized trial","volume":"12","author":"Zunica","year":"2024","journal-title":"Physiol Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib245","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.metabol.2010.01.001","article-title":"Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus","volume":"60","author":"Cuthbertson","year":"2011","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib246","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib247","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib248","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","article-title":"Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial","volume":"2","author":"Diamant","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9951","key":"10.1016\/j.pharmr.2025.100106_bib249","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib250","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN forte): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10193","key":"10.1016\/j.pharmr.2025.100106_bib251","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100106_bib252","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib253","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (Pioneer 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10192","key":"10.1016\/j.pharmr.2025.100106_bib254","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (Pioneer 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib255","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib256","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib257","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharmr.2025.100106_bib258","doi-asserted-by":"crossref","DOI":"10.1038\/srep32714","article-title":"The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib259","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/dom.14059","article-title":"Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB)","volume":"22","author":"Kitazawa","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"39","key":"10.1016\/j.pharmr.2025.100106_bib260","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008161","article-title":"Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Med (Baltim)"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib261","doi-asserted-by":"crossref","first-page":"e4593","DOI":"10.1210\/clinem\/dgaa577","article-title":"Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis","volume":"105","author":"Lingvay","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125879","article-title":"Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis","volume":"10","author":"Mearns","year":"2015","journal-title":"PLOS One"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib263","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmr.2025.100106_bib264","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244432","article-title":"Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review","volume":"14","author":"Xie","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11-12","key":"10.1016\/j.pharmr.2025.100106_bib265","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.pharmr.2025.100106_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108921","article-title":"GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials","volume":"177","author":"Tsapas","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100106_bib267","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehaa777","article-title":"Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin","volume":"42","author":"Ferrannini","year":"2021","journal-title":"Eur Heart J"},{"issue":"9902","key":"10.1016\/j.pharmr.2025.100106_bib268","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"issue":"9840","key":"10.1016\/j.pharmr.2025.100106_bib269","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"issue":"10208","key":"10.1016\/j.pharmr.2025.100106_bib270","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100106_bib271","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the Pioneer 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib272","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bcp.13807","article-title":"Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis","volume":"85","author":"Inoue","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib273","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100778","article-title":"Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus","volume":"9","author":"Napolitano","year":"2014","journal-title":"PLOS One"},{"issue":"5754","key":"10.1016\/j.pharmr.2025.100106_bib274","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","article-title":"Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib276","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/me.2004-0211","article-title":"Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3\/Foxa transactivation via inhibition of its DNA binding","volume":"18","author":"Kim","year":"2004","journal-title":"Mol Endocrinol"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100106_bib277","doi-asserted-by":"crossref","first-page":"23158","DOI":"10.1074\/jbc.M314322200","article-title":"Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and FOXO1","volume":"279","author":"Yamagata","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib278","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/JOE-09-0345","article-title":"Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5","volume":"205","author":"Caton","year":"2010","journal-title":"J Endocrinol"},{"issue":"7219","key":"10.1016\/j.pharmr.2025.100106_bib279","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature07349","article-title":"A fasting inducible switch modulates gluconeogenesis via activator\/coactivator exchange","volume":"456","author":"Liu","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib280","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2006.04.013","article-title":"GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha","volume":"3","author":"Lerin","year":"2006","journal-title":"Cell Metab"},{"issue":"7241","key":"10.1016\/j.pharmr.2025.100106_bib281","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Cant\u00f3","year":"2009","journal-title":"Nature"},{"issue":"30","key":"10.1016\/j.pharmr.2025.100106_bib282","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1074\/jbc.M114.567271","article-title":"Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK)","volume":"289","author":"Cao","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib283","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M114.604421","article-title":"Metformin activates AMP-activated protein kinase by promoting formation of the \u03b1\u03b2\u03b3 heterotrimeric complex","volume":"290","author":"Meng","year":"2015","journal-title":"J Biol Chem"},{"issue":"7899","key":"10.1016\/j.pharmr.2025.100106_bib284","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib285","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib286","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib287","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ijo.2010.40","article-title":"Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study","volume":"34","author":"Garinis","year":"2010","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib288","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pharep.2018.10.013","article-title":"Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease","volume":"71","author":"Handzlik","year":"2019","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib289","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5448.2008.00450.x","article-title":"Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents","volume":"10","author":"Nadeau","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib290","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100106_bib291","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib292","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/diabetes.53.8.2169","article-title":"Effects of Rosiglitazone and Metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes","volume":"53","author":"Tiikkainen","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib293","first-page":"1","article-title":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"32","author":"Associazione Italiana per lo Studio del Fegato (AISF)","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib294","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrm3997","article-title":"A giant molecular proton pump: structure and mechanism of respiratory complex I","volume":"16","author":"Sazanov","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib296","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jcmm.13432","article-title":"Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation","volume":"22","author":"Hou","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib297","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1074\/jbc.M306766200","article-title":"Mitochondrial pH monitored by a new engineered green fluorescent protein mutant","volume":"279","author":"Abad","year":"2004","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100106_bib298","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1073\/pnas.95.12.6803","article-title":"Measurement of cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins","volume":"95","author":"Llopis","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib299","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122287119","article-title":"Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis","volume":"119","author":"LaMoia","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7436","key":"10.1016\/j.pharmr.2025.100106_bib300","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib301","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41591-018-0125-4","article-title":"Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo","volume":"24","author":"Madiraju","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib302","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbabio.2012.11.014","article-title":"The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues","volume":"1827","author":"Mr\u00e1\u010dek","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100106_bib303","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1111\/febs.16164","article-title":"The mitochondrial coenzyme Q junction and complex III: biochemistry and pathophysiology","volume":"289","author":"Banerjee","year":"2022","journal-title":"FEBS Journal"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib304","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.30507","article-title":"Deficiency of mitochondrial glycerol 3-phosphate dehydrogenase contributes to hepatic steatosis","volume":"70","author":"Zheng","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2025.100106_bib305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2022.06.092","article-title":"Mitochondrial GCN5L1 regulates cytosolic redox state and hepatic gluconeogenesis via glycerol phosphate shuttle GPD2","volume":"621","author":"Meng","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100106_bib306","doi-asserted-by":"crossref","first-page":"25041","DOI":"10.1074\/jbc.M702031200","article-title":"Citrin\/mitochondrial glycerol-3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency","volume":"282","author":"Saheki","year":"2007","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib307","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1074\/jbc.RA118.006670","article-title":"Low metformin causes a more oxidized mitochondrial NADH\/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism","volume":"294","author":"Alshawi","year":"2019","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib308","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2337\/db20-1143","article-title":"Metformin\u2019s therapeutic efficacy in the treatment of diabetes does not involve inhibition of mitochondrial glycerol phosphate dehydrogenase","volume":"70","author":"MacDonald","year":"2021","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib309","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/dmd.30.8.861","article-title":"Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect","volume":"30","author":"Stepensky","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-3659(00)00374-6","article-title":"Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation","volume":"71","author":"Stepensky","year":"2001","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib311","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tips.2023.04.004","article-title":"Striking a gut-liver balance for the antidiabetic effects of metformin","volume":"44","author":"Barroso","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib312","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1476-5381.1994.tb13128.x","article-title":"Importance of the intestine as a site of metformin-stimulated glucose utilization","volume":"112","author":"Bailey","year":"1994","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib313","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.1992.tb09093.x","article-title":"Effect of metformin on glucose metabolism in the splanchnic bed","volume":"105","author":"Bailey","year":"1992","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib314","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211933120","article-title":"Metformin acts in the gut and induces gut-liver crosstalk","volume":"120","author":"Tobar","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib315","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/dom.12812","article-title":"Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes","volume":"19","author":"Wu","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib316","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/s41598-019-42531-0","article-title":"Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport","volume":"9","author":"Horakova","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib317","first-page":"301","article-title":"Metformin-induced regulation of the intestinal D-glucose transporters","volume":"61","author":"Sakar","year":"2010","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib318","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106057","article-title":"Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes","volume":"26","author":"Zubiaga","year":"2023","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib319","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1007\/s11033-023-08535-w","article-title":"The role of GLUT2 in glucose metabolism in multiple organs and tissues","volume":"50","author":"Sun","year":"2023","journal-title":"Mol Biol Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib320","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-014-3451-1","article-title":"GLUT2, glucose sensing and glucose homeostasis","volume":"58","author":"Thorens","year":"2015","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib321","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0006-2952(95)02243-0","article-title":"Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats","volume":"51","author":"Lenzen","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib322","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13340-021-00545-y","article-title":"Metformin action in the gut-insight provided by [(18)F]FDG PET imaging","volume":"13","author":"Tsuchida","year":"2022","journal-title":"Diabetol Int"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib323","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","article-title":"High and typical 18F-FDG bowel uptake in patients treated with metformin","volume":"35","author":"Gontier","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.pharmr.2025.100106_bib324","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.diabres.2017.07.015","article-title":"Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: results from a randomized clinical trial","volume":"131","author":"Koffert","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib325","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2214\/AJR.10.4663","article-title":"Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin","volume":"195","author":"Oh","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib326","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3748\/wjg.v24.i7.775","article-title":"Glucose transporter expression in the human colon","volume":"24","author":"Merigo","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib327","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035240","article-title":"Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms","volume":"7","author":"Lin","year":"2012","journal-title":"PLOS One"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib328","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib329","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/dom.13567","article-title":"Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes","volume":"21","author":"Borg","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib330","first-page":"336","article-title":"Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes","volume":"17","author":"Mannucci","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"10.1016\/j.pharmr.2025.100106_bib331","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2025.100106_bib332","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170342","article-title":"Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms","volume":"131","author":"Krieger","year":"2020","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib333","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1464-5491.2009.02748.x","article-title":"Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes","volume":"26","author":"Cuthbertson","year":"2009","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib334","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00535-012-0637-5","article-title":"Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells","volume":"48","author":"Kappe","year":"2013","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/JOE-13-0381","article-title":"Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling","volume":"220","author":"Kim","year":"2014","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib336","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz025","article-title":"Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology","volume":"105","author":"Br\u00f8nden","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100106_bib337","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.physiol.64.082201.100300","article-title":"Bile salt transporters","volume":"64","author":"Meier","year":"2002","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib338","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1463-1326.2002.00223.x","article-title":"Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells","volume":"4","author":"Carter","year":"2002","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib339","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1463-1326.2003.00252.x","article-title":"Differential effects of metformin on bile salt absorption from the jejunum and ileum","volume":"5","author":"Carter","year":"2003","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib340","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00429833","article-title":"Inhibition of bile salt absorption by blood-sugar lowering biguanides","volume":"11","author":"Caspary","year":"1975","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib341","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/(SICI)1096-9136(199808)15:8<651::AID-DIA628>3.0.CO;2-A","article-title":"Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus","volume":"15","author":"Scarpello","year":"1998","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib342","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100106_bib343","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00125-012-2593-2","article-title":"Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers","volume":"55","author":"Adrian","year":"2012","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib344","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/dom.12648","article-title":"Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion","volume":"18","author":"Hansen","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/dom.12043","article-title":"Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans","volume":"15","author":"Wu","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib346","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12876-017-0736-0","article-title":"Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial","volume":"18","author":"Tiessen","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100106_bib347","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136873","article-title":"Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice","volume":"10","author":"Briere","year":"2015","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib348","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib349","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/dom.12636","article-title":"Therapeutic potential of Takeda-G-Protein-receptor-5 (TGR5) agonists. Hope or hype?","volume":"18","author":"Hodge","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib350","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.cmet.2008.11.002","article-title":"Glucose sensing in L cells: a primary cell study","volume":"8","author":"Reimann","year":"2008","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib351","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/jphysiol.2008.164012","article-title":"Nutritional regulation of glucagon-like peptide-1 secretion","volume":"587","author":"Tolhurst","year":"2009","journal-title":"J Physiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib352","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1530\/JME-16-0099","article-title":"AMPK-dependent regulation of GLP1 expression in L-like cells","volume":"57","author":"Jiang","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib353","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149549","article-title":"Proglucagon promoter Cre-mediated AMPK deletion in mice increases circulating GLP-1 levels and oral glucose tolerance","volume":"11","author":"Sayers","year":"2016","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib354","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41467-022-28743-5","article-title":"Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100106_bib355","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101183","article-title":"Deletion of intestinal epithelial AMP-activated protein kinase alters distal colon permeability but not glucose homeostasis","volume":"47","author":"Olivier","year":"2021","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib356","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib357","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/genes8100250","article-title":"Effects of antidiabetic drugs on gut microbiota composition","volume":"8","author":"Montandon","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pharmr.2025.100106_bib358","article-title":"Effects of metformin on the gut microbiota: A systematic review","volume":"77","author":"Pavlo","year":"2023","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib359","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib360","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2337\/dc16-1324","article-title":"Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut","volume":"40","author":"de la Cuesta-Zuluaga","year":"2017","journal-title":"Diabetes Care"},{"issue":"7581","key":"10.1016\/j.pharmr.2025.100106_bib361","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100106_bib362","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108985","article-title":"Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids","volume":"178","author":"Lee","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib363","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1042\/BCJ20210073","article-title":"GLUT4 on the move","volume":"479","author":"Fazakerley","year":"2022","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib364","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/BST20221066","article-title":"Insulin signalling and GLUT4 trafficking in insulin resistance","volume":"51","author":"van Gerwen","year":"2023","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib365","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1139\/H07-026","article-title":"Role of Akt substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport","volume":"32","author":"Cartee","year":"2007","journal-title":"Appl Physiol Nutr Metab"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100106_bib366","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1210\/mend.11.13.0027","article-title":"Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells","volume":"11","author":"Cong","year":"1997","journal-title":"Mol Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib367","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2337\/db06-0175","article-title":"AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits","volume":"55","author":"Treebak","year":"2006","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib368","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/BJ20050887","article-title":"AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain","volume":"391","author":"M\u00eeinea","year":"2005","journal-title":"Biochem J"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100106_bib369","doi-asserted-by":"crossref","first-page":"14599","DOI":"10.1074\/jbc.C300063200","article-title":"Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation","volume":"278","author":"Sano","year":"2003","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100106_bib370","doi-asserted-by":"crossref","first-page":"9187","DOI":"10.1074\/jbc.M708934200","article-title":"Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation","volume":"283","author":"Chavez","year":"2008","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib371","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1074\/jbc.RA118.004614","article-title":"Cooperative actions of Tbc1d1 and AS160\/Tbc1d4 in GLUT4-trafficking activities","volume":"294","author":"Hatakeyama","year":"2019","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100106_bib372","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.bjp.0704878","article-title":"Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells","volume":"137","author":"Kumar","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib373","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diabetes.51.1.30","article-title":"Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects","volume":"51","author":"Ciaraldi","year":"2002","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib374","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2337\/diab.40.7.850","article-title":"Association of metformin\u2019s effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes","volume":"40","author":"Matthaei","year":"1991","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib375","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1042\/bj3480083","article-title":"Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin","volume":"348","author":"Pryor","year":"2000","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib376","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1210\/endo.133.1.8391425","article-title":"In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa\/fa) Zucker rat adipocytes","volume":"133","author":"Matthaei","year":"1993","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib377","doi-asserted-by":"crossref","first-page":"C1549","DOI":"10.1152\/ajpcell.00279.2010","article-title":"Genetic downregulation of AMPK-alpha isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells","volume":"299","author":"Bogachus","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100106_bib378","doi-asserted-by":"crossref","first-page":"25226","DOI":"10.1074\/jbc.M202489200","article-title":"The Anti-diabetic drugs Rosiglitazone and Metformin stimulate AMP-activated protein kinase through distinct signaling pathways","volume":"277","author":"Fryer","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib379","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcp.22410","article-title":"Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells","volume":"226","author":"Lee","year":"2011","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib380","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1152\/japplphysiol.00255.2006","article-title":"Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo","volume":"101","author":"Suwa","year":"2006","journal-title":"J Appl Physiol (1985)"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100106_bib381","doi-asserted-by":"crossref","first-page":"E1099","DOI":"10.1152\/ajpendo.00417.2013","article-title":"Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle","volume":"306","author":"Kristensen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2025.100106_bib382","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.metabol.2018.11.010","article-title":"Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPK\u03b1","volume":"91","author":"Yan","year":"2019","journal-title":"Metabolism"},{"issue":"7640","key":"10.1016\/j.pharmr.2025.100106_bib383","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib384","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J Clin Invest"},{"issue":"48","key":"10.1016\/j.pharmr.2025.100106_bib385","doi-asserted-by":"crossref","first-page":"35279","DOI":"10.1074\/jbc.M706762200","article-title":"A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways","volume":"282","author":"Nguyen","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib386","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100106_bib387","doi-asserted-by":"crossref","first-page":"G107","DOI":"10.1152\/ajpgi.00391.2009","article-title":"Kupffer cell activation is a causal factor for hepatic insulin resistance","volume":"298","author":"Lanthier","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100106_bib388","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100106_bib389","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/jpem-2011-0469","article-title":"The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial","volume":"25","author":"Evia-Viscarra","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100106_bib390","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00592-011-0276-y","article-title":"The effects of Rosiglitazone and Metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus","volume":"48","author":"Fidan","year":"2011","journal-title":"Acta Diabetol"},{"issue":"33","key":"10.1016\/j.pharmr.2025.100106_bib391","doi-asserted-by":"crossref","first-page":"23246","DOI":"10.1074\/jbc.M114.577908","article-title":"Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction","volume":"289","author":"Kim","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100106_bib392","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2337\/db14-1225","article-title":"Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis","volume":"64","author":"Vasamsetti","year":"2015","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100106_bib393","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0006-2952(99)00396-2","article-title":"Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine","volume":"59","author":"Ikeda","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100106_bib394","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110347","article-title":"Xanthosine, a purine glycoside mediates hepatic glucose homeostasis through inhibition of gluconeogenesis and activation of glycogenesis via regulating the AMPK\/FoxO1\/AKT\/GSK3\u03b2 signaling cascade","volume":"371","author":"Ahmed","year":"2023","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharmr.2025.100106_bib395","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.biopha.2018.10.077","article-title":"Involvement of AMPK activation in the inhibition of hepatic gluconeogenesis by Ficus carica leaf extract in diabetic mice and HepG2 cells","volume":"109","author":"Zhang","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100106_bib396","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","article-title":"Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment","volume":"9","author":"Pel\u00e1ez-Jaramillo","year":"2018","journal-title":"Diabetes Ther"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:20:10Z","timestamp":1770132010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725075155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":395,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0031699725075155"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100106","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin\u2014mechanisms of its glycemia-reducing effect","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100106"}}